- [Alt + 0] - Startseite
- [Alt + 1] - Navigation
- [Alt + 2] - Inhalt
- [Alt + 3] - Contact
- [Alt + 4] - Sitemap
- [Alt + 5] - Search
Navegación con Teclas de Acceso
Noticias Recientes
Octapharma wins major tender victory in Norway
21.12.2012
LACHEN, Switzerland (20th December 2012) Octapharma was recently awarded an extension of the exclusivity contract for virus inactivated plasma, Octaplas, with all Norwegian hospitals for four more years. Today Norway...
Octapharma opens €25 million recombinant research facility in Heidelberg
27.09.2012
LACHEN, Switzerland (28th September, 2012) – Octapharma AG today announces the opening of a €25 million research facility dedicated to recombinant protein drug development in Heidelberg, Germany. Octapharma...
Octapharma hosts symposium at WFH World Congress on meeting the challenges of von Willebrand Disease (VWD) diagnosis and treatment
23.07.2012
LACHEN, Switzerland (July, 23, 2012) − Octapharma AG, a leading producer of human proteins for life saving therapies, sponsored the symposium entitled “Meeting the challenges of VWD diagnosis and treatment- Which problems...
Octapharma hosts symposium at WFH World Congress on “Personalizing the Inhibitor Treatment and Prevention” in haemophilia A
20.07.2012
LACHEN, Switzerland (July 20th, 2012) – Octapharma AG, a leading producer of human proteins for life saving therapies, proudly sponsored an octanate® symposium entitled “Personalizing the Inhibitor Treatment and Prevention: New...
Octapharma is presenting two scientific symposia on Immune Tolerance Induction in Haemophilia A and von Willebrand Disease at World Federation of Haemophilia World Congress 2012 in Paris
05.07.2012
Octapharma AG announces the sponsorship of two scientific symposia during the 2012 World Congress of World Federation of Haemophilia (WFH) held in Paris from July 8 -12, 2012. Octapharma is a leading producer of human proteins...
Octapharma USA expands access to octagam® 5% for participating 340B healthcare facilities
26.06.2012
Initiative Focuses on Providing IGIV to Underserved Patients
Octapharma Group releases 2011 Annual Report
30.03.2012
2011 has been a successful transitional year for the Octapharma Group. Since octagam® 5% and 10% re-entered all important markets profitability experienced a month-by-month continuous improvement. Re-entry combined with the...